Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epigenetic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Epigenetic. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2018-002267-25 Sponsor Protocol Number: SEOTP-2018 Start Date*: 2018-07-18
    Sponsor Name:Fakultní nemocnice Brno
    Full Title: SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE
    Medical condition: Psychoses
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001238-21 Sponsor Protocol Number: 2020-SESGEN Start Date*: 2021-07-06
    Sponsor Name:Institute of Health and Biomedical Research of Alicante
    Full Title: Gender biases in pain medicine: from omics to healthcare.
    Medical condition: The medical condition to be evaluated is the analgesic response of people with chronic low back pain who are going to be treated with opioids, guided by omics sciences (pharmacogenetics, epigeneti...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004444-31 Sponsor Protocol Number: KWMP001 Start Date*: 2015-01-09
    Sponsor Name:
    Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or...
    Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000197-30 Sponsor Protocol Number: UoL001289 Start Date*: 2018-07-13
    Sponsor Name:The University of Liverpool
    Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia
    Medical condition: High Risk Oral Epithelial Dysplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-006151-20 Sponsor Protocol Number: D1449L00029 Start Date*: 2006-08-29
    Sponsor Name:University of Erlangen-Nuremberg
    Full Title: Quetiapine and the dopaminergic epigenetic control – a pilot study
    Medical condition: Patients suffering from schizophrenia (ICD10: F20.x) Healthy controls
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002097-38 Sponsor Protocol Number: ABR62020 Start Date*: 2018-06-05
    Sponsor Name:University Medical Centre Utrecht
    Full Title: SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial
    Medical condition: Depressive episode in people with childhood trauma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006189-19 Sponsor Protocol Number: NL2021-13291 Start Date*: 2022-01-12
    Sponsor Name:Radboudumc
    Full Title: Trained immunity by dual-pathway inhibition (low-dose rivaroxaban and acetylsalicylic acid) in coronary artery disease
    Medical condition: coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002521-19 Sponsor Protocol Number: FSH_IMEN Start Date*: 2015-10-19
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: "Pilot study on the effect of FSH treatment in epigenetic characteristics of sperm in infertile patients with severe oligozoospermia"
    Medical condition: Male infertility
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10017399 FSH LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001639-38 Sponsor Protocol Number: MDS/2013 Start Date*: 2016-12-06
    Sponsor Name:1st Dep. of Medicine, General University Hospital (VFN) in Prague
    Full Title: Contribution to verify the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy 5 - Azacitidine patients with the high risk Myelodysplastic syndrome.
    Medical condition: Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005629-65 Sponsor Protocol Number: RG_12-269 Start Date*: 2014-01-15
    Sponsor Name:University of Birmingham
    Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study
    Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-003779-37 Sponsor Protocol Number: IOM-080-2 Start Date*: 2009-02-05
    Sponsor Name:iOMEDICO AG
    Full Title: Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients
    Medical condition: HER-2/neu negative metastatic or locally advanced inoperable breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003299-15 Sponsor Protocol Number: METFORAGING Start Date*: 2021-10-19
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz
    Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi...
    Medical condition: Patients with HIV and accelerated biological aging
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005158-12 Sponsor Protocol Number: NCT-2017-0530 Start Date*: 2019-04-01
    Sponsor Name: Ruprecht-Karls-University Heidelberg Medical Faculty, University Hospital
    Full Title: TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach
    Medical condition: Patients with confirmed diagnosis of Acute Myeloid Leukemia (AML)according to WHO-2016 classification (except acute promyelocytic leukemia) either de novo AML, AML after preceding myelodysplastic o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022844-19 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Dijon
    Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
    Medical condition: Hodgkin Lymphoma not previously treated
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003689-41 Sponsor Protocol Number: CRAD001YGB11 Start Date*: 2012-11-19
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e...
    Medical condition: oestrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002456-21 Sponsor Protocol Number: 74082 Start Date*: 2020-05-28
    Sponsor Name:Radboudumc
    Full Title: Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS)
    Medical condition: Trained immunity COVID-19 This study will investigate whether oral bisphosphonate supplementation or the MMR vaccine can be used as immune potentiators when simultaneously administered with BCG, t...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002995-29 Sponsor Protocol Number: CNTO1959PSO3009 Start Date*: 2017-05-10
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
    Medical condition: Moderate to Severe Plaque-Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 11:12:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA